Towards an integrated immunotherapy approach for melanoma using herpes simplex virus type-1 derived oncolytic viruses

Philipp Kalus; Jolien De Munck; Yannick De Vlaeminck; Katrijn Broos; Ivan Van Riet; Bart Neyns; Karine Breckpot; Joeri Aerts

Towards an integrated immunotherapy approach for melanoma using herpes simplex virus type-1 derived oncolytic viruses

Philipp Kalus, Jolien De Munck, Yannick De Vlaeminck, Katrijn Broos, Ivan Van Riet, Bart Neyns, Karine Breckpot, Joeri Aerts

Research output: Unpublished contribution to conference › Poster

Abstract

In recent years, oncolytic viruses (OVs) have proven to be a promising tool for antitumor immunotherapy. They induce tumor killing while providing immunogenic
structures, both contributing to augmented antitumor immune responses. Recent studies pinpointed immunogenic cell death (ICD) of eliminated cells as a crucial
determinant for initiation of an adequate immune response. Here, we investigated the immunogenicity of cell death of melanoma cells induced by Herpes Simplex
Virus type-1 (HSV-1) derived OVs and the possibility to skew cell death in an immunogenic direction by overexpressing cell death mediating proteins (CDMPs).

Original language	English
Publication status	Unpublished - Jun 2018

Cite this

@conference{aab96643d5a34c81801d84dba594ced2,

title = "Towards an integrated immunotherapy approach for melanoma using herpes simplex virus type-1 derived oncolytic viruses",

abstract = "In recent years, oncolytic viruses (OVs) have proven to be a promising tool for antitumor immunotherapy. They induce tumor killing while providing immunogenicstructures, both contributing to augmented antitumor immune responses. Recent studies pinpointed immunogenic cell death (ICD) of eliminated cells as a crucialdeterminant for initiation of an adequate immune response. Here, we investigated the immunogenicity of cell death of melanoma cells induced by Herpes SimplexVirus type-1 (HSV-1) derived OVs and the possibility to skew cell death in an immunogenic direction by overexpressing cell death mediating proteins (CDMPs).",

author = "Philipp Kalus and {De Munck}, Jolien and {De Vlaeminck}, Yannick and Katrijn Broos and {Van Riet}, Ivan and Bart Neyns and Karine Breckpot and Joeri Aerts",

year = "2018",

month = jun,

language = "English",

}

TY - CONF

T1 - Towards an integrated immunotherapy approach for melanoma using herpes simplex virus type-1 derived oncolytic viruses

AU - Kalus, Philipp

AU - De Munck, Jolien

AU - De Vlaeminck, Yannick

AU - Broos, Katrijn

AU - Van Riet, Ivan

AU - Neyns, Bart

AU - Breckpot, Karine

AU - Aerts, Joeri

PY - 2018/6

Y1 - 2018/6

N2 - In recent years, oncolytic viruses (OVs) have proven to be a promising tool for antitumor immunotherapy. They induce tumor killing while providing immunogenicstructures, both contributing to augmented antitumor immune responses. Recent studies pinpointed immunogenic cell death (ICD) of eliminated cells as a crucialdeterminant for initiation of an adequate immune response. Here, we investigated the immunogenicity of cell death of melanoma cells induced by Herpes SimplexVirus type-1 (HSV-1) derived OVs and the possibility to skew cell death in an immunogenic direction by overexpressing cell death mediating proteins (CDMPs).

AB - In recent years, oncolytic viruses (OVs) have proven to be a promising tool for antitumor immunotherapy. They induce tumor killing while providing immunogenicstructures, both contributing to augmented antitumor immune responses. Recent studies pinpointed immunogenic cell death (ICD) of eliminated cells as a crucialdeterminant for initiation of an adequate immune response. Here, we investigated the immunogenicity of cell death of melanoma cells induced by Herpes SimplexVirus type-1 (HSV-1) derived OVs and the possibility to skew cell death in an immunogenic direction by overexpressing cell death mediating proteins (CDMPs).

M3 - Poster

ER -

Towards an integrated immunotherapy approach for melanoma using herpes simplex virus type-1 derived oncolytic viruses

Abstract

Fingerprint

Cite this